EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Effect of Admission Diabetes History on Safety and Efficacy of Early Tirofiban Infusion after Intravenous Thrombolysis in Ischaemic Stroke: a post-hoc analysis of the ASSET-IT trial

Li Wang, Chunrong Tao, Cong Luo, Yuerong Chen, Yuyou Zhu, Pengfei Xu, Rui Li, Tianlong Liu, Chao Zhang, Jianlong Song, Jiangping Cui, Jun Sun und 2 weitere

European Stroke Journal · 06.07.2026 · 11 (7)

DOI: 10.1093/esj/aakag076 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Stroke Journal, online erschienen am 13.07.2026. Verfasst von Li Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Cheeloo College of Medicine, Shandong University, Jinan 250000, China. Hauptthemen laut MEDLINE: Tirofiban, Thrombolytic Therapy, Fibrinolytic Agents, Ischemic Stroke. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Clinical and Translational Research Project of Anhui Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study aimed to investigate how diabetes mellitus (DM) influences the efficacy of early tirofiban administration after intravenous thrombolysis in patients with acute ischaemic noncardioembolic stroke. Patients and methods This was a post-hoc analysis of the ASSET-IT (Advancing Stroke Safety and Efficacy through Early Tirofiban Administration after Intravenous Thrombolysis) trial. Patients were categorised into DM and non-DM groups based on baseline diabetes history. The primary efficacy outcome was an excellent functional outcome at 90 days, defined as an mRS score of 0–1. Safety outcomes included sICH within 36 h, any ICH and all-cause mortality within 90 days. The effect of diabetes on treatment outcomes was assessed using multivariable regression models adjusting for relevant confounders.

Results

A total of 832 patients at 38 centres were randomised in the ASSET-IT trial (414 to tirofiban, 418 to placebo). The median age was 69 years (IQR, 59–76); 301 (36.2%) were women. Overall, 191 patients (23.0%) had diabetes mellitus. Among patients without diabetes, an excellent functional outcome at 90 days occurred in 69.0% of patients in the tirofiban group and 55.8% in the placebo group, whereas among patients with diabetes, the corresponding rates were 55.0% and 52.0%, respectively. The nominal P value for the treatment-by-diabetes interaction was .009. The 90-day mortality was higher in the DM group receiving tirofiban (6.6% vs 2.0%; RR, 3.79; 95% CI, 0.84–17.05; P = .082) but not in the non-DM group (3.4% vs 4.4%; RR, 0.82; 95% CI, 0.40–1.70; P = .597).

Conclusion

Exploratory post-hoc findings from the ASSET-IT trial suggest that the association between early tirofiban administration after intravenous thrombolysis and 90-day functional outcomes may differ according to diabetes status. These hypothesis-generating observations require confirmation in prospective studies with pre-specified subgroup analyses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TirofibanThrombolytic TherapyFibrinolytic AgentsIschemic StrokeDiabetes MellitusHumansFemaleMaleTreatment OutcomeAgedMiddle AgedInfusions, Intravenous

Stichwörter der Autor:innen

diabetes mellitusstrokethrombolysistirofiban

Substanzen

TirofibanFibrinolytic Agents

Autor:innen und Institutionen

  • Cheeloo College of Medicine, Shandong University, Jinan 250000, China.
  • Department of Neurology, First Affiliated Hospital of the University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.
  • The First Clinical Medical College of Anhui Medical University, Anhui Medical University, Hefei 230001, China.

Förderung

  • Clinical and Translational Research Project of Anhui Province

Zitieren

APA

Wang, L., Tao, C., Luo, C., Chen, Y., Zhu, Y., Xu, P., Li, R., Liu, T., Zhang, C., Song, J., Cui, J., Sun, J., Hu, W., & Liu, X. (2026). Effect of Admission Diabetes History on Safety and Efficacy of Early Tirofiban Infusion after Intravenous Thrombolysis in Ischaemic Stroke: a post-hoc analysis of the ASSET-IT trial. European Stroke Journal, 11(7). https://doi.org/10.1093/esj/aakag076

Vancouver

Wang L, Tao C, Luo C, Chen Y, Zhu Y, Xu P, et al. Effect of Admission Diabetes History on Safety and Efficacy of Early Tirofiban Infusion after Intravenous Thrombolysis in Ischaemic Stroke: a post-hoc analysis of the ASSET-IT trial. European Stroke Journal. 2026;11(7). doi:10.1093/esj/aakag076

BibTeX
@article{Wang2026,
  author = {Wang, Li and Tao, Chunrong and Luo, Cong and Chen, Yuerong and Zhu, Yuyou and Xu, Pengfei and Li, Rui and Liu, Tianlong and Zhang, Chao and Song, Jianlong and Cui, Jiangping and Sun, Jun and Hu, Wei and Liu, Xinfeng},
  title = {Effect of Admission Diabetes History on Safety and Efficacy of Early Tirofiban Infusion after Intravenous Thrombolysis in Ischaemic Stroke: a post-hoc analysis of the ASSET-IT trial},
  journal = {European Stroke Journal},
  year = {2026},
  volume = {11},
  number = {7},
  doi = {10.1093/esj/aakag076}
}
Kostenlos starten →